Grants and Contributions:

Back to search

Title:

COVID-19 Response (VI): DPX-COVID-19 Clinical Development and DPX-CoVLP Proof-of-Concept Study

Agreement Number:

957553

Agreement Value:

$2,655,429.00

Agreement Date:

Sep 4, 2020 - Aug 31, 2022

Description:

In response to the global crisis, IMV has initiated the development of a vaccine to protect against the COVID-19 pandemic. We believe our targeted peptide epitope approach has the potential to optimize and exceed the safety and efficacy profile of more conventional vaccines. DPX-COVID-19 utilizes a multi-target approach, to optimize immune response against virus’ weaknesses, enhance efficacy at preventing infection and reduce potential for immune escape, even in case of a virus mutation. Fully synthetic, DPX-COVID-19 has the potential for fast and large-scale manufacturing to supply a significant number of doses rapidly compared to more conventional vaccines.

Organization:

National Research Council Canada

Expected Results:

The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization

Location:

Dartmouth, Nova Scotia, CA B3B 2C4

Reference Number:

172-2020-2021-Q3-957553

Agreement Type:

Contribution

Report Type:

Grants and Contributions

Recipient Business Number:

864736772

Recipient Type:

For-profit organization

Additional Information:

This agreement has been amended 1 time(s). The total amended value is -1,135,750 dollars.

Amendment Date

Feb 27, 2023

Recipient's Legal Name:

ImmunoVaccine Technologies Inc.

Federal Riding Name:

Dartmouth--Cole Harbour

Federal Riding Number:

12004

Program:

Industrial Research Assistance Program – Contributions to Firms

Program Purpose:

Coverage:

IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.

NAICS Code:

325410

Amendments:

See Amendments